Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Antipsychotics Market to 2017 - Introduction | 7 | 1 |
| GBI Report Guidance | 7 | 1 |
| Antipsychotics Market to 2017 - Global Market Overview | 8 | 10 |
| Introduction | 8 | 1 |
| Revenue Forecasts | 9 | 1 |
| Generic Share | 10 | 1 |
| Annual Cost of Treatment | 11 | 1 |
| Top Antipsychotics Drug Products | 12 | 1 |
| Seroquel (quetiapine) | 13 | 1 |
| Zyprexa (olanzapine) | 13 | 1 |
| Abilify (aripiprazole) | 14 | 1 |
| Risperdal (risperidone) | 14 | 1 |
| Geodon (ziprasidone) | 14 | 1 |
| Newer Antipsychotics | 15 | 1 |
| Fanapt (iloperidone) | 15 | 1 |
| Saphris / Sycrest (asenapine) | 16 | 1 |
| Invega Sustenna (paliperidone palmitate extended release injectable suspension) | 16 | 1 |
| Latuda (lurasidone Hcl) | 17 | 1 |
| Antipsychotics Market to 2017 - Geographical Landscape | 18 | 8 |
| Revenue Analysis by Geography | 18 | 1 |
| The US | 19 | 1 |
| Revenue | 19 | 1 |
| Annual Cost of Treatment | 20 | 1 |
| Top Five Countries of Europe | 21 | 1 |
| Revenue | 21 | 2 |
| Annual Cost of Treatment | 23 | 1 |
| Japan - Antipsychotics Market | 24 | 1 |
| Revenue | 24 | 1 |
| Annual Cost of Treatment | 25 | 1 |
| Antipsychotics Market to 2017 - Therapeutic Landscape | 26 | 18 |
| Bipolar Disorder - Antipsychotics Market | 26 | 1 |
| Introduction | 26 | 1 |
| Treatment Algorithm | 27 | 1 |
| Revenue | 28 | 3 |
| Annual Cost of Treatment | 31 | 1 |
| Treatment Usage Patterns | 32 | 1 |
| Diseased Population | 33 | 1 |
| Treatment Seeking Population | 33 | 1 |
| Diagnosis Population | 33 | 1 |
| Prescription Population | 33 | 1 |
| Drivers and Barriers to the Antipsychotics Market for Bipolar Disorder | 34 | 1 |
| Drivers for Bipolar Disorder Therapeutics Market | 34 | 1 |
| Increase in Patient Volume May Drive the Market Growth in Future | 34 | 1 |
| Barriers for Bipolar Disorder Therapeutics Market | 34 | 1 |
| Upcoming Patent Expiries of Antipsychotics | 34 | 1 |
| Low Diagnosis Rate of Bipolar Disorder | 34 | 1 |
| Relatively High Prescription Share to Lithium Carbonates and Side Effects Associated With Use of Antipsychotics | 35 | 1 |
| Schizophrenia - Antipsychotics Market | 35 | 1 |
| Introduction | 35 | 1 |
| Treatment Algorithm | 36 | 1 |
| Revenue | 37 | 3 |
| Annual Cost of Treatment | 40 | 1 |
| Treatment Usage Patterns | 41 | 1 |
| Diseased Population | 42 | 1 |
| Treatment Seeking Population | 42 | 1 |
| Diagnosis Population | 42 | 1 |
| Prescription Population | 42 | 1 |
| Drivers and Barriers to the Antipsychotics Market for Schizophrenia | 43 | 1 |
| Drivers for the Schizophrenia Therapeutics Market | 43 | 1 |
| Disease Population Growth | 43 | 1 |
| Expected Launch of Pipeline Molecules | 43 | 1 |
| Barriers for the Schizophrenia Therapeutics Market | 43 | 1 |
| Low Treatment Seeking Behavior | 43 | 1 |
| Patent Expiries of Major Drugs | 43 | 1 |
| Antipsychotics Market to 2017 - Product Pipeline Analysis | 44 | 10 |
| Introduction | 44 | 2 |
| Antipsychotics Market to 2017- Discovery Stage Molecules | 46 | 1 |
| Antipsychotics Market to 2017- Pre-clinical Stage Molecules | 47 | 1 |
| Antipsychotics Market to 2017- Phase I Stage Molecules | 48 | 2 |
| Antipsychotics Market to 2017- Phase II Stage Molecules | 50 | 2 |
| Antipsychotics Market to 2017- Phase III Stage Molecules | 52 | 1 |
| Antipsychotics Market to 2017- NDA Filed Molecules | 52 | 1 |
| NDA filed molecules | 52 | 1 |
| AZ-004 | 52 | 2 |
| Antipsychotics Market to 2017 - Competitive Landscape | 54 | 6 |
| Market Share Analysis | 54 | 1 |
| AstraZeneca | 55 | 1 |
| Business Overview | 55 | 1 |
| SWOT Analysis | 55 | 1 |
| Eli Lilly | 56 | 1 |
| Business Overview | 56 | 1 |
| SWOT Analysis | 56 | 1 |
| Bristol-Myers Squibb (BMS) | 57 | 1 |
| Business Overview | 57 | 1 |
| SWOT Analysis | 57 | 1 |
| Johnson &Johnson (J&J) | 58 | 1 |
| Business Overview | 58 | 1 |
| SWOT Analysis | 58 | 1 |
| Pfizer | 59 | 1 |
| Business Overview | 59 | 1 |
| SWOT Analysis | 59 | 1 |
| Antipsychotics Market to 2017 - M&A Landscape | 60 | 20 |
| M&A Deals (2007-2011) | 61 | 1 |
| M&A Deals by Region | 61 | 1 |
| M&A Deals by Value | 62 | 1 |
| M&A Deals by Year | 63 | 2 |
| Summary of M&A Deals (2009-2011) | 65 | 1 |
| Alexza Pharmaceuticals Acquires Symphony Allegro from Symphony Capital | 65 | 1 |
| Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals | 65 | 1 |
| Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion | 65 | 1 |
| Proximagen Neuroscience Acquires Minster Pharmaceuticals | 65 | 1 |
| Biovail Acquires Valeant Pharmaceuticals | 66 | 1 |
| Sigma-Aldrich Acquires Cerilliant from Argenta Partners | 66 | 1 |
| Biotie Therapies Acquires Synosia Therapeutics | 66 | 1 |
| Ligand Pharmaceuticals Acquires CyDex Pharmaceuticals | 66 | 1 |
| Nuvo Research Acquires ZARS Pharma | 67 | 1 |
| Licensing Deals | 67 | 3 |
| Licensing Deals by Region | 70 | 1 |
| Licensing Deals by Year | 71 | 1 |
| Deal Summary (2010-2011) | 72 | 1 |
| Alexza Pharmaceuticals Enters Into Licensing Agreement with Biovail Laboratories | 72 | 1 |
| Obecure Enters Into Licensing Agreement with Farmaceutici Formenti | 72 | 1 |
| Azur Pharma Enters Into Licensing Agreement with Douglas Pharmaceuticals | 72 | 1 |
| Cypress Bioscience Enters Into Licensing Agreement with BioLineRx | 72 | 1 |
| Marquette University Enters Licensing Agreement with AviMed Pharmaceuticals | 73 | 1 |
| Meiji Seika Kaisha Enters Into Licensing Agreement with RaQualia Pharma For Ziprasidone | 73 | 1 |
| Dainippon Sumitomo Pharma Enters Into Licensing Agreement with Takeda Pharmaceutical for Lurasidone | 73 | 1 |
| Co-development Deals | 74 | 2 |
| Co-development Deals by Region | 76 | 1 |
| Co-development Deals by Year | 77 | 1 |
| Deal Summary (2010 - 2011) | 78 | 1 |
| International Serious Adverse Event Consortium Enters Into Collaboration Agreement with Duke University | 78 | 1 |
| Targacept Expands Its Collaboration Agreement with AstraZeneca | 78 | 1 |
| Takeda Pharmaceutical Enters Into Research Agreement with Envoy Therapeutics | 78 | 1 |
| Johns Hopkins Brain Science Institute Enters Into an Agreement with Ortho-McNeil-Janssen | 79 | 1 |
| Takeda Pharmaceutical Enters Into Co-Development Agreement with Kyoto University | 79 | 1 |
| Intra-Cellular Therapies Enters Into Collaboration with Takeda Pharmaceutical | 79 | 1 |
| Antipsychotics Market to 2017 - Appendix | 80 | 8 |
| Market Definitions | 80 | 1 |
| Abbreviations | 80 | 1 |
| Research Methodology | 81 | 6 |
| Coverage | 81 | 1 |
| Secondary Research | 81 | 1 |
| Primary Research | 82 | 1 |
| Therapeutic Landscape | 82 | 1 |
| Epidemiology-based Forecasting | 83 | 1 |
| Market Size by Geography | 84 | 2 |
| Geographical Landscape | 86 | 1 |
| Pipeline Analysis | 86 | 1 |
| Competitive Landscape | 86 | 1 |
| Expert Panel Validation | 86 | 1 |
| Contact Us | 86 | 1 |
| Disclaimer | 86 | 1 |
| Sources | 87 | 1 |